Secukinumab in plaque psoriasis—results of two phase 3 trials
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Interleukin-17A is considered to be central to the pathogenesis of psoriasis. We evaluated secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe plaque psoriasis. METHODS: In two phase 3, double-blind, 52-week trials, ERASURE (Efficacy of Response and Safety of Two Fixed Secukinumab Regimens in Psoriasis) and FIXTURE (Full Year Investigative Examination of Secukinumab vs. Etanercept Using Two Dosing Regimens to Determine Efficacy in Psoriasis), we randomly assigned 738 patients (in the ERASURE study) and 1306 patients (in the FIXTURE study) to subcutaneous secukinumab at a dose of 300 mg or 150 mg (administered once weekly for 5 weeks, then every 4 weeks), placebo, or (in the FIXTURE study only) etanercept at a dose of 50 mg (administered twice weekly for 12 weeks, then once weekly). The objective of each study was to show the superiority of secukinumab over placebo at week 12 with respect to the proportion of patients who had a reduction of 75% or more from baseline in the psoriasis area-and-severity index score (PASI 75) and a score of 0 (clear) or 1 (almost clear) on a 5-point modified investigator's global assessment (coprimary end points). RESULTS: The proportion of patients who met the criterion for PASI 75 at week 12 was higher with each secukinumab dose than with placebo or etanercept: in the ERASURE study, the rates were 81.6% with 300 mg of secukinumab, 71.6% with 150 mg of secukinumab, and 4.5% with placebo; in the FIXTURE study, the rates were 77.1% with 300 mg of secukinumab, 67.0% with 150 mg of secukinumab, 44.0% with etanercept, and 4.9% with placebo (P<0.001 for each secukinumab dose vs. comparators). The proportion of patients with a response of 0 or 1 on the modified investigator's global assessment at week 12 was higher with each secukinumab dose than with placebo or etanercept: in the ERASURE study, the rates were 65.3% with 300 mg of secukinumab, 51.2% with 150 mg of secukinumab, and 2.4% with placebo; in the FIXTURE study, the rates were 62.5% with 300 mg of secukinumab, 51.1% with 150 mg of secukinumab, 27.2% with etanercept, and 2.8% with placebo (P<0.001 for each secukinumab dose vs. comparators). The rates of infection were higher with secukinumab than with placebo in both studies and were similar to those with etanercept. CONCLUSIONS: Secukinumab was effective for psoriasis in two randomized trials, validating interleukin-17A as a therapeutic target. (Funded by Novartis Pharmaceuticals; ERASURE and FIXTURE ClinicalTrials.gov numbers, NCT01365455 and NCT01358578, respectively.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“An Ab targeting IL-17 (secukinumab) was approved in 2016 to treat moderate-severe plaque psoriasis [54].”
From The Kallikrein-Kinin System: A Novel Mediator of IL-17-Driven Anti-Candida Immunity in the Kidney (2016) · cites this paper as [54]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use
FINLAY, A. Y., & KHAN, G. K. (1994) · Clinical and Experimental Dermatology · doi:10.1111/j.1365-2230.1994.tb01167.x · Cited by 5,586
Harrington, L. E., Hatton, R. D., Mangan, P. R., Turner, H., Murphy, T. L., Murphy, K. M., & Weaver, C. T. (2005) · Nature Immunology · doi:10.1038/ni1254 · Cited by 4,742
A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17
Park, H., Li, Z., Yang, X. O., Chang, S. H., Nurieva, R., Wang, Y.-H., Wang, Y., Hood, L., Zhu, Z., Tian, Q., et al. (2005) · Nature Immunology · doi:10.1038/ni1261 · Cited by 4,265
Pathogenesis and clinical features of psoriasis
Griffiths, C. E., & Barker, J. N. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61128-3 · Cited by 2,158
Chronic Mucocutaneous Candidiasis in Humans with Inborn Errors of Interleukin-17 Immunity
Puel, A., Cypowyj, S., Bustamante, J., Wright, J. F., Liu, L., Lim, H. K., Migaud, M., Israel, L., Chrabieh, M., Audry, M., et al. (2011) · Science · doi:10.1126/science.1200439 · Cited by 1,056
Pivotal Role of Dermal IL-17-Producing γδ T Cells in Skin Inflammation
Cai, Y., Shen, X., Ding, C., Qi, C., Li, K., Li, X., Jala, V. R., Zhang, H.-G., Wang, T., Zheng, J., et al. (2011) · Immunity · doi:10.1016/j.immuni.2011.08.001 · Cited by 1,026
Mast Cells and Neutrophils Release IL-17 through Extracellular Trap Formation in Psoriasis
Lin, A. M., Rubin, C. J., Khandpur, R., Wang, J. Y., Riblett, M., Yalavarthi, S., Villanueva, E. C., Shah, P., Kaplan, M. J., & Bruce, A. T. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1100123 · Cited by 906
Interleukin-17 and its target genes: mechanisms of interleukin-17 function in disease
Onishi, R. M., & Gaffen, S. L. (2010) · Immunology · doi:10.1111/j.1365-2567.2009.03240.x · Cited by 894
Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis
Griffiths, C. E. M., Strober, B. E., van de Kerkhof, P., Ho, V., Fidelus-Gort, R., Yeilding, N., Guzzo, C., Xia, Y., Zhou, B., Li, S., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0810652 · Cited by 859
Harper, E. G., Guo, C., Rizzo, H., Lillis, J. V., Kurtz, S. E., Skorcheva, I., Purdy, D., Fitch, E., Iordanov, M., & Blauvelt, A. (2009) · Journal of Investigative Dermatology · doi:10.1038/jid.2009.65 · Cited by 508
Cited by
Items 601–700 of 1,001
Chiricozzi, A., Balato, A., Conrad, C., Conti, A., Dapavo, P., Ferreira, P., Gaiani, F. M., Leite, L., Malagoli, P., Mendes‐Bastos, P., et al. (2019) · Journal of Dermatological Treatment · doi:10.1080/09546634.2019.1671577 · Cited by 41
Schneider, A., Mueller, P., Jordi, C., Richard, P., Sneeringer, P., Nayyar, R., Yovanoff, M., & Lange, J. (2019) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2020.1704730 · Cited by 42
“0 300 Clinical development Monthly [35,56] Tralokinumab Asthma LEO Pharma PFS 2.”
BackgroundCai, J., Cui, L., Wang, Y., Li, Y., Zhang, X., & Shi, Y. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.774808 · Cited by 47
The Role of the Neutrophilic Network in the Pathogenesis of Psoriasis
Czerwińśka, J., & Owczarczyk-Saczonek, A. B. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031840 · Cited by 46
Managing Scalp Psoriasis: An Evidence-Based Review
Wang, T., & Tsai, T. (2016) · American Journal of Clinical Dermatology · doi:10.1007/s40257-016-0222-4 · Cited by 40
Blauvelt, A., Reich, K., Warren, R. B., Szepietowski, J. C., Sigurgeirsson, B., Tyring, S. K., Messina, I., Bhosekar, V., Oliver, J., Papavassilis, C., et al. (2017) · British Journal of Dermatology · doi:10.1111/bjd.15656 · Cited by 40
Self-citationProtection from Psoriasis-Related Thrombosis after Inhibition of IL-23 or IL-17A
Li, Y., Golden, J. B., Camhi, M. I., Zhang, X., Fritz, Y., Diaconu, D., Ivanco, T. L., Simon, D. I., Kikly, K. K., McCormick, T. S., et al. (2017) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2017.09.021 · Cited by 40
“, 2017]); ixekizumab and secukinumab (IL-17A [Gordon et al., 2016; Langley et al., 2014]); and brodalumab (IL-17RA [Blauvelt et al.”
BackgroundEmerging Associations Between Neutrophils, Atherosclerosis, and Psoriasis
Sanda, G. E., Belur, A. D., Teague, H., & Mehta, N. N. (2017) · Current Atherosclerosis Reports · doi:10.1007/s11883-017-0692-8 · Cited by 46
Eaton, L. H., Mellody, K. T., Pilkington, S. M., Dearman, R. J., Kimber, I., & Griffiths, C. E. M. (2017) · British Journal of Dermatology · doi:10.1111/bjd.16172 · Cited by 45
Dokoupilová, E., Aelion, J. A., Takeuchi, T., Malavolta, N., Sfikakis, P., Wang, Y., Rohrer, S., & Richards, H. (2018) · Scandinavian Journal of Rheumatology · doi:10.1080/03009742.2017.1390605 · Cited by 44
Gottlieb, A. B., Kubanov, A. A., van Doorn, M. B. A., Sullivan, J. R., Papp, K. A., You, R., Regnault, P., & Frueh, J. (2019) · British Journal of Dermatology · doi:10.1111/bjd.18331 · Cited by 40
Pharmacodynamics OF TNF α inhibitors for the treatment of psoriasis
Campanati, A., Paolinelli, M., Diotallevi, F., Martina, E., Molinelli, E., & Offidani, A. (2019) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2019.1681969 · Cited by 47
Biologics in Psoriasis: Updated Perspectives on Long-Term Safety and Risk Management
Al‐Janabi, A., & Yiu, Z. Z. N. (2022) · Psoriasis Targets and Therapy · doi:10.2147/ptt.s328575 · Cited by 56
Treatment goals for psoriasis: Should PASI 90 become the standard of care?
Torres, T. R., & Puig, L. (2015) · Actas Dermo-Sifiliográficas · doi:10.1016/j.adengl.2014.10.005 · Cited by 63
Interleukin 17-A inhibition in the treatment of psoriasis
Yiu, Z. Z. N., & Griffiths, C. E. M. (2015) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.2016.1112739 · Cited by 40
“As IL-17 is important in immunological protection against infections, especially against candida, is there any evidence of increased infections in patients treated with IL17A inhibitors? Neutropenia has been noted as an AE in trials involving secukinumab,[7] ixekizumab [1] and brodalumab, [3,8] which may predispose th…”
BackgroundBai, J. P. F., Schmidt, B. J., Gadkar, K. G., Damian, V., Earp, J. C., Friedrich, C., van der Graaf, P. H., Madabushi, R., Musante, C. J., Naik, K., et al. (2021) · The AAPS Journal · doi:10.1208/s12248-021-00585-x · Cited by 38
Zhang, C., Yan, K., Diao, Q., Guo, Q., Jin, H., Yang, S., Chen, X., Lei, T., Wu, J., Yu, H., et al. (2022) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2022.01.005 · Cited by 41
The current state of knowledge of the immune ecosystem in alopecia areata
Connell, S. J., & Jabbari, A. (2022) · Autoimmunity Reviews · doi:10.1016/j.autrev.2022.103061 · Cited by 44
Iversen, L., Conrad, C., Eidsmo, L., Costanzo, A., Narbutt, J., Pinter, A., Kingo, K., Diaz, R. R., Kolbinger, F., Nanna, M., et al. (2023) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.18846 · Cited by 47
“17 In two pivotal Phase III trials of secukinumab in patients with moderate to severe plaque psoriasis, the average disease duration at baseline was ~17 years.(9) The STEPIn study is the first to investigate the impact of early treatment with a biologic on sustained skin clearance in patients with new- onset psoriasis…”
BackgroundResultA Review of Psoriasis, Therapies, and Suicide
Gooderham, M., Gavino-Velasco, J., Clifford, C., MacPherson, A., Krasnoshtein, F., & Papp, K. A. (2016) · Journal of Cutaneous Medicine and Surgery · doi:10.1177/1203475416648323 · Cited by 44
“001).(28) In PsA, treatment with 300, 150, or 75 mg secukinumab (n = 397) resulted in improvements in Health Assessment Questionnaire–Disability Index scores at week 24 with a 300mg dose compared with placebo.”
BackgroundMethodCurrent and Emerging Therapies for Itch Management in Psoriasis
Stull, C. M., Grossman, S. K., & Yosipovitch, G. (2016) · American Journal of Clinical Dermatology · doi:10.1007/s40257-016-0213-5 · Cited by 39
Moots, R. J., Curiale, C., Petersel, D. L., Rolland, C., Jones, H. E., & Mysler, E. (2018) · BioDrugs · doi:10.1007/s40259-018-0283-4 · Cited by 39
Ontong, J. C., Lambert, S., Furnholm, T., Roberts, L., Reingold, L. J., Auepemkiate, S., Voravuthikunchai, S. P., & Johnston, A. (2018) · PLoS ONE · doi:10.1371/journal.pone.0205340 · Cited by 42
Cost-Effectiveness of Targeted Pharmacotherapy for Moderate to Severe Plaque Psoriasis
Hendrix, N., Ollendorf, D. A., Chapman, R. H., Loos, A. M., Liu, S., Kumar, V., Linder, J. A., Pearson, S. D., & Veenstra, D. L. (2018) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2018.24.12.1210 · Cited by 44
Stein, S., Henze, L., Poch, T., Carambia, A., Krech, T., Preti, M., Schuran, F. A., Reich, M., Keitel, V., Fiorotto, R., et al. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2020.10.035 · Cited by 38
Discovery of novel pyrazole-containing benzamides as potent RORγ inverse agonists
Wang, T., Banerjee, D., Bohnert, T., Chao, J., Enyedy, I. J., Fontenot, J. D., Guertin, K. R., Jones, H., Lin, E. Y.-S., Marcotte, D. J., et al. (2015) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2015.05.028 · Cited by 39
English version of Japanese guidance for use of biologics for psoriasis (the 2022 version)
Saeki, H., Mabuchi, T., Asahina, A., Abe, M., Igarashi, A., Imafuku, S., Okubo, Y., Komine, M., Sano, S., Torii, H., et al. (2022) · The Journal of Dermatology · doi:10.1111/1346-8138.16691 · Cited by 38
Therapeutic Advancements in Psoriasis and Psoriatic Arthritis
Yi, R. C., Akbik, M., Smith, L. R., Klionsky, Y. Z., & Feldman, S. R. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14041312 · Cited by 38
A novel therapeutic paradigm for patients with extensive alopecia areata
Renert‐Yuval, Y., & Guttman‐Yassky, E. (2016) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2016.1188076 · Cited by 39
“[29,34,39] Secukinumab is a recombinant, high-affinity, fully human IgG1κ monoclonal antibody that selectively inhibits IL-17A (Figure 1), that is highly efficacious in psoriasis.[33] In psoriasis, blockade of IL-17 suppressed the expression of both downstream and upstream genes, notably both IL-23p40 and IL-23p19 gen…”
BackgroundThe IL-17-Th1/Th17 pathway: an attractive target for lung cancer therapy?
Joerger, M., Finn, S. P., Cuffe, S. D., Byrne, A. T., & Gray, S. G. (2016) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2016.1206891 · Cited by 42
“However, it must be noted that most common AE during the entire treatment period included nasopharyngitis, headache, and upper respiratory infection [93], which may have implications for treating patients with”
BackgroundBlauvelt, A., Papp, K. A., Griffiths, C. E. M., Puig, L., Weisman, J. D., Dutronc, Y., Kerr, L. F., Ilo, D., Mallbris, L., & Augustin, M. (2017) · American Journal of Clinical Dermatology · doi:10.1007/s40257-016-0246-9 · Cited by 41
Successful Secukinumab treatment of generalized pustular psoriasis and erythrodermic psoriasis
Mugheddu, C., Atzori, L., Lappi, A., Pau, M., Murgia, S., & Rongioletti, F. (2017) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.14234 · Cited by 38
Biologics in patients with skin diseases
Veilleux, M. S., & Shear, N. H. (2017) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2017.03.012 · Cited by 39
“Apart from 3 severe mucocutaneous cases reported in the UNCOVER-2 trial (1 affecting the external ear during the induction period and 2 affecting the oral mucosa between 12 and 60weeks of treatment), all cases reportedweremild tomoderate.(12) No systemic Candida species infection has been reported with the anti–IL-17…”
BackgroundFunctional and phenotypic heterogeneity of Th17 cells in health and disease
Byström, J., Clanchy, F. I. L., Taher, T. E. I., Al-Bogami, M. M., Ong, V. H., Abraham, D., Williams, R. O., & Mageed, R. A. (2018) · European Journal of Clinical Investigation · doi:10.1111/eci.13032 · Cited by 41
“The role of Th17 cells in psoriatic patients was thereafter verified by the effective therapeutic effect of human IgG1κ monoclonal antibodies targeting IL‐17A and IL‐17RA (Table 2).(68) As cited earlier, at least in mice, some tissue‐resident T cells recognize C.”
BackgroundFeldman, S. R., Tian, H., Wang, X., & Germino, R. (2018) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2018.18308 · Cited by 46
on behalf of the FUTURE 2 study group, Coates, L. C., Gladman, D. D., Nash, P. T., FitzGerald, O., Kavanaugh, A., Kvien, T. K., Gossec, L., Strand, V., Rasouliyan, L., et al. (2018) · Arthritis Research & Therapy · doi:10.1186/s13075-018-1773-y · Cited by 38
The pharmacological management of patients with comorbid psoriasis and obesity
Chiricozzi, A., Gisondi, P., & Girolomoni, G. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1583207 · Cited by 42
“Body weight gain has not been observed in patients receiving secukinumab in ERASURE and FIXTURE clinical trials [46].”
BackgroundSafety concerns with current treatments for psoriasis in the elderly
Caprio, R. D., Caiazzo, G., Cacciapuoti, S., Fabbrocini, G., Scala, E., & Balato, A. (2020) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2020.1728253 · Cited by 40
“CLEAR) [77,83] analyzed the safety of SCK at the recommended dose (300 mg) in elderly subjects, showing a comparable rate of AEs between elderly (82.”
Emerging Therapeutic Options for Chronic Pruritus
Reszke, R., Krajewski, P. K., & Szepietowski, J. C. (2020) · American Journal of Clinical Dermatology · doi:10.1007/s40257-020-00534-y · Cited by 41
Li, X., Lau, S. K. P., & Woo, P. C. Y. (2020) · Experimental Biology and Medicine · doi:10.1177/1535370220939862 · Cited by 40
“2% in the etanercept group.(60) All these candida infections were local and mild to moderate in severity, and none resulted in chronic mucocutaneous candidiasis or treatment discontinuation.”
BackgroundGottlieb, A. B., Merola, J. F., Reich, K., Behrens, F., Nash, P. T., Griffiths, C. E. M., Bao, W., Pellet, P., Pricop, L., & McInnes, I. B. (2021) · British Journal of Dermatology · doi:10.1111/bjd.20413 · Cited by 38
Yi, K., Jo, S., Song, W., Lee, H.-I., Kim, H., Kang, J., Kim, S. U., Lee, S. H., Park, J., Kim, T., et al. (2023) · Arthritis & Rheumatology · doi:10.1002/art.42476 · Cited by 45
“Moreover, antibody therapies targeting IL-17A have been ineffective for bowel inflammation or uveitis in AS (13,14), in contrast to the marked effectiveness for psoriasis (15,16).”
ResultExpert consensus on the persistence of biological treatments in moderate‐to‐severe psoriasis
de la Cueva, P., Notario, J., Ferrándiz, C., López-Estebaranz, J. L., Alarcón, I., Sulleiro, S., Borrás, J., Daudén, E., Carrascosa, J. M., Carazo, J. L. S., et al. (2019) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.15600 · Cited by 42
Distinct roles of interleukin-17 and T helper 17 cells among autoimmune diseases
Akiyama, S., & Sakuraba, A. (2021) · Journal of Translational Autoimmunity · doi:10.1016/j.jtauto.2021.100104 · Cited by 47
Biologics for Reducing Cardiovascular Risk in Psoriasis Patients
Terui, H., & Asano, Y. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12031162 · Cited by 41
“These IL-17 inhibitors have also shown efficacy against psoriatic skin lesions in direct comparative studies with etanercept and ustekinumab [18,112,113].”
BackgroundAdvances in therapeutic strategies for the treatment of pruritus
Stull, C. M., Lavery, M. J., & Yosipovitch, G. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2016.1127355 · Cited by 38
“Medication Mechanism of Action Indication Developmental Status Crisaborole PDE4 antagonist Atopic dermatitis Phase 3 evaluation of topical ointment in children, adolescents and adults Psoriasis Phase 2 evaluation of topical ointment in adults CT327 TrkA antagonist Atopic dermatitis Phase 2 evaluation of topical ointme…”
BackgroundInfluentialFurue, M., & Kadono, T. (2016) · The Journal of Dermatology · doi:10.1111/1346-8138.13186 · Cited by 42
Future perspectives in target-specific immunotherapies of myasthenia gravis
Dalakas, M. C. (2015) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756285615605700 · Cited by 37
2016 Addendum to the Canadian Guidelines for the Management of Plaque Psoriasis 2009
Papp, K. A., Gulliver, W. P. F., Lynde, C. W., Poulin, Y. P., Adam, D., Barankin, B., Barber, K. A., Bourcier, M., Gooderham, M., Guenther, L., et al. (2016) · Journal of Cutaneous Medicine and Surgery · doi:10.1177/1203475416655705 · Cited by 47
“The recommended dose for patients weighing more than 100 kg is 90 mg, which should also be administered at weeks 0 and 4 and every 12 weeks thereafter.(27) In cases where a loss of response was detected in patients, an improved response was seen when the dosage was increased from 45 mg ustekinumab every 12 weeks to 90…”
BackgroundVerstockt, B., Deleenheer, B., Assche, G. V., Vermeire, S., & Ferrante, M. (2017) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2017.1338273 · Cited by 39
“In a pooled analysis of patients with psoriasis, secukinumab treatment and the occurrence or exacerbation of IBD did not appear to be related, but this should be carefully interpreted as this observation may be due to a low sample size [72].”
BackgroundGuselkumab for the Treatment of Psoriasis
Machado, Á., & Torres, T. R. (2018) · BioDrugs · doi:10.1007/s40259-018-0265-6 · Cited by 43
“These agents have been approved to treat moderate to severe psoriasis [9–11] and have shown high levels of sustained efficacy and better clinical responses than TNF-a inhibitors [12, 13] and ustekinumab [10, 14, 15].”
Schnute, M. E., Wennerstål, M., Alley, J., Bengtsson, M., Blinn, J. R., Bolten, C. W., Braden, T., Bonn, T., Carlsson, B., Caspers, N. L., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00392 · Cited by 42
Therapies in ankylosing spondylitis—from clinical trials to clinical practice
Tahir, H. (2018) · Lara D. Veeken · doi:10.1093/rheumatology/key152 · Cited by 37
Kimball, A. B., Papp, K. A., Reich, K., Gooderham, M., Li, Q., Cichanowitz, N., Rosa, C. L., & Blauvelt, A. (2019) · British Journal of Dermatology · doi:10.1111/bjd.18484 · Cited by 37
Kiltz, U., Sfikakis, P. P., Gaffney, K., Sator, P.-G., von Kiedrowski, R., Bounas, A., Gullick, N., Conrad, C., Rigopoulos, D., Lespessailles, É., et al. (2020) · Advances in Therapy · doi:10.1007/s12325-020-01352-8 · Cited by 38
Effectiveness and Safety of Anti-interleukin-17 Therapies in Elderly Patients with Psoriasis
Phan, C., Bénéton, N., Delaunay, J., Reguiaï, Z., Boulard, C., Fougerousse, A., Cinotti, É., Romanelli, M., Mery‐Bossard, L., Thomas‐Beaulieu, D., et al. (2020) · Acta Dermato Venereologica · doi:10.2340/00015555-3678 · Cited by 41
Pagliari, D., Gambassi, G., Piccirillo, C. A., & Cianci, R. (2017) · Mediators of Inflammation · doi:10.1155/2017/8390595 · Cited by 41
“However, this trial failed in this disease but it had satisfactory results in psoriasis [101].”
ResultImmunotherapies in chronic pain through modulation of neuroimmune interactions
Zhao, J., Huh, Y., Bortsov, A. V., Diatchenko, L. B., & Ji, R. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108476 · Cited by 43
Finley, P. J., DeClue, C. E., Sell, S. A., DeBartolo, J. M., & Shornick, L. P. (2015) · Advances in Wound Care · doi:10.1089/wound.2015.0676 · Cited by 38
Schaarschmidt, M., Herr, R. M., Gutknecht, M., Wroblewska, K., Gerdes, S., Sticherling, M., Augustin, M., & Peitsch, W. K. (2017) · Acta Dermato Venereologica · doi:10.2340/00015555-2834 · Cited by 37
Secukinumab in the treatment of psoriasis: patient selection and perspectives
Yang, E., Beck, K. M., & Liao, W. J. (2018) · Psoriasis Targets and Therapy · doi:10.2147/ptt.s146004 · Cited by 46
“Secukinumab was compared with placebo in ERASURE and placebo or etanercept in FIXTURE.”
BackgroundMethodInfluentialDisrupting the CD95–PLCγ1 interaction prevents Th17-driven inflammation
Poissonnier, A., Guégan, J., Nguyen, H. T., Best, D., Levoin, N., Kozlov, G., Gehring, K., Pineau, R., Jouan, F., Morere, L., et al. (2018) · Nature Chemical Biology · doi:10.1038/s41589-018-0162-9 · Cited by 38
Chen, S., Paveley, R. A., Kraal, L., Sritharan, L., Stevens, E., Dedi, N., Shock, A., Shaw, S., Juárez, M., Yeremenko, N. G., et al. (2020) · Journal of Autoimmunity · doi:10.1016/j.jaut.2020.102435 · Cited by 36
Loft, N., Halling, A., Egeberg, A., & Skov, L. (2020) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2020.07.085 · Cited by 41
Talamonti, M., Malara, G., Natalini, Y., Bardazzi, F., Conti, A., Chiricozzi, A., Mugheddu, C., Gisondi, P., Piaserico, S., Pagnanelli, G., et al. (2020) · Acta Dermato Venereologica · doi:10.2340/00015555-3712 · Cited by 40
Xian, J., Shang, M., Dai, Y., Wang, Q., Long, X., Li, J., Cai, Y., Xia, C., & Peng, X. (2021) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2021.11.007 · Cited by 38
Psoriasis during pregnancy: characteristics and important management recommendations
Hoffman, M. B., Farhangian, M. E., & Feldman, S. R. (2015) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.2015.1037742 · Cited by 36
“Secukinumab, a human monoclonal antibody against IL-17, has just recently been approved for the treatment of moderate-to-severe psoriasis after two randomized trials have validated its efficacy [128].”
BackgroundCharacterization of Il-17Aa and Il-17Ff in Rheumatoid Arthritis and Multiple Sclerosis
Schofield, C., Fischer, S. K., Townsend, M. J., Mosesova, S., Peng, K., Setiadi, A. F., Song, A., & Baruch, A. (2016) · Bioanalysis · doi:10.4155/bio-2016-0207 · Cited by 39
“Several antibody therapeutics that inhibit IL-17A or its respective receptor have been evaluated in clinical trials, including secukinumab (Cosentyx ® ), ixeki-zumab and brodalumab, which target IL-17 for RA and psoriasis [13–15] .”
Yogarajah, J., Gouveia, C., Iype, J. M., Haefliger, S., Schaller, A., Nuoffer, J., Fux, M., & Gautschi, M. (2021) · Skin Health and Disease · doi:10.1002/ski2.25 · Cited by 43
“Secukinumab has been reported to be fast and effective in the reduction of psoriasis symptoms.(7) During the induction period, this prompt efficacy was observed in our patient; erythema and scaling, showed striking improvement.”
BackgroundChildhood guttate psoriasis: an updated review
Leung, A. K. C., Barankin, B., Lam, J. M., & Leong, K. F. (2023) · Drugs in Context · doi:10.7573/dic.2023-8-2 · Cited by 49
Yan, K., Li, F., Bi, X., Han, L., Zhang, Z., Chen, R., Li, Y., Zhang, L., Wang, X., Li, L., et al. (2024) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2024.09.031 · Cited by 39
Iskandar, I. Y. K., Ashcroft, D. M., Warren, R. B., Lunt, M., McElhone, K., Smith, C. H., Reynolds, N. J., & Griffiths, C. E. M. (2017) · British Journal of Dermatology · doi:10.1111/bjd.15531 · Cited by 35
Interstitial Pneumonia in Psoriasis
Kawamoto, H., Hara, H., Minagawa, S., Numata, T., Araya, J., Kaneko, Y., Umezawa, Y., Asahina, A., Nakagawa, H., & Kuwano, K. (2018) · Mayo Clinic Proceedings Innovations Quality & Outcomes · doi:10.1016/j.mayocpiqo.2018.07.006 · Cited by 38
McMichael, A. J., Desai, S. R., Qureshi, A., Rastogi, S., & Alexis, A. F. (2018) · American Journal of Clinical Dermatology · doi:10.1007/s40257-018-0408-z · Cited by 35
Biologics for chronic inflammatory skin diseases: an update for the clinician
Yao, Y., Jørgensen, A. R., & Thomsen, S. F. (2019) · Journal of Dermatological Treatment · doi:10.1080/09546634.2019.1589643 · Cited by 37
“is overexpressed in psoriatic skin and correlates to the onset of the disease (29).”
BackgroundSecukinumab in the Treatment of Palmoplantar, Nail, Scalp, and Pustular Psoriasis.
Armstrong, A. W., Vender, R. B., & Kircik, L. (2016) · Europe PMC (PubMed Central) · Cited by 41
Rompoti, N., Sidiropoulou, P., Panagakis, P., Stratigos, A. J., Papoutsaki, M., Stefanaki, E. C., Vavouli, C., Politou, M., Befon, A., Kostakis, P. G., et al. (2020) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.16202 · Cited by 35
Brodalumab: A new way to inhibit IL ‐17 in psoriasis
Facheris, P., Valenti, M., Pavia, G., Guanziroli, E., Narcisi, A., Borroni, R. G., & Costanzo, A. (2020) · Dermatologic Therapy · doi:10.1111/dth.13403 · Cited by 39
“vs Etanercept Using Two Dosing Regimens to Determine Efficacy in Psoriasis), were conducted.(20) Patients were randomly assigned (738 patients in the ERASURE study and 1306 patients in the FIX-”
MethodPetty, A. J., Whitley, M. J., Balaban, A., Ellington, K. S., & Marano, A. L. (2020) · JAAD Case Reports · doi:10.1016/j.jdcr.2020.06.011 · Cited by 35
“Common adverse effects of secukinumab include nasopharyngitis and candidiasis.(3) Although development of pyoderma gangrenosum has been reported for the use of tumor necrosis factor a inhibitors in patients with psoriasis,(4) pyoderma gangrenosum has never been linked to IL-17 antagonists in the United States.”
BackgroundReich, K., Armstrong, A. W., Foley, P. A., Song, M., Miller, M. J., Shen, Y., You, Y., Han, C., & Gordon, K. B. (2020) · American Journal of Clinical Dermatology · doi:10.1007/s40257-020-00555-7 · Cited by 38
Perspectives on the Genetic Associations of Ankylosing Spondylitis
Wordsworth, B. P., Cohen, C., Davidson, C., & Vecellio, M. L. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.603726 · Cited by 41
“Thus, targeting of IL-17 (the main proinflammatory cytokine associated with terminally differentiated Th17 cells) with the therapeutic monoclonal antibodies secukinumab or ixekizumab has proved highly successful in AS (37, 38) and psoriasis (39) but not IBD (40).”
BackgroundNew Frontiers in Psoriatic Disease Research, Part II: Comorbidities and Targeted Therapies
Yan, D., Blauvelt, A., Dey, A. K., Golpanian, R. S., Hwang, S. T., Mehta, N. N., Myers, B. A., Shi, Z., Yosipovitch, G., Bell, S. J., et al. (2021) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2021.02.743 · Cited by 40
Blauvelt, A., Armstrong, A. W., Langley, R. G. B., Gebauer, K., Thaçi, D., Bagel, J., Guenther, L., Paul, C. F., Randazzo, B. P., Flavin, S. K., et al. (2021) · Journal of Dermatological Treatment · doi:10.1080/09546634.2021.1959504 · Cited by 39
Self-citationFala, L. (2016) · Europe PMC (PubMed Central) · Cited by 35
Pharmacologic Treatment Strategies in Psoriatic Arthritis
Ayan, G., Ribeiro, A. L., Macit, B., & Proft, F. N. (2023) · Clinical Therapeutics · doi:10.1016/j.clinthera.2023.05.010 · Cited by 36
Armstrong, A. W., Warren, R. B., Zhong, Y., Zhuo, J., Cichewicz, A. B., Kadambi, A., Junqueira, D. R., Westley, T., Kisa, R. M., Daamen, C., et al. (2023) · Dermatology and Therapy · doi:10.1007/s13555-023-01034-7 · Cited by 42
Ma, L., Yang, W., Gao, W., Liu, X., Dong, M., An, G., & Meng, X. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107879 · Cited by 42
Unintended Immunological Consequences of Biologic Therapy
Henrickson, S. E., Ruffner, M. A., & Kwan, M. (2016) · Current Allergy and Asthma Reports · doi:10.1007/s11882-016-0624-7 · Cited by 39
Artificial macrocycles as IL-17A/IL-17RA antagonists
Wang, W., Groves, M. R., & Dömling, A. S. S. (2018) · MedChemComm · doi:10.1039/c7md00464h · Cited by 34
Adverse Reactions to Biologics in Psoriasis
Lockwood, S. J., Prens, L. M., & Kimball, A. B. (2017) · Current problems in dermatology · doi:10.1159/000478072 · Cited by 38
Wu, D., Yue, J., & Tam, L. (2017) · Rheumatology · doi:10.1093/rheumatology/kex452 · Cited by 35
Therapeutic Response to Secukinumab in a 36-Year-Old Woman with Hidradenitis Suppurativa
Jørgensen, A. R., Yao, Y., & Thomsen, S. F. (2018) · Case Reports in Dermatological Medicine · doi:10.1155/2018/8685136 · Cited by 38
Bayaraa, B., & Imafuku, S. (2019) · The Journal of Dermatology · doi:10.1111/1346-8138.14834 · Cited by 36
Fujita, H., Ohtsuki, M., Morita, A., Nagao, R., Seko, N., Matsumoto, K., Tani, Y., & Terui, T. (2020) · The Journal of Dermatology · doi:10.1111/1346-8138.15655 · Cited by 34
T cell immunity to commensal fungi
Scheffold, A., Bächer, P., & LeibundGut‐Landmann, S. (2020) · Current Opinion in Microbiology · doi:10.1016/j.mib.2020.09.008 · Cited by 38
“albicans infections in psoriasis patients treated with IL-17-targetting antibodies [50,51] indicates that interfering with the IL17 response can modulate the mycobiota.”
BackgroundGastroenterological safety of IL-17 inhibitors: a systematic literature review
Caron, B., Jouzeau, J., Miossec, P., Petitpain, N., Gillet, P., Netter, P., & Peyrin‐Biroulet, L. (2021) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2021.1960981 · Cited by 36
Ma, V. T.-L., Lao, C. D., Fecher, L. A., & Schiopu, E. (2022) · Immunotherapy · doi:10.2217/imt-2021-0274 · Cited by 38
Singh, J. A., Guyatt, G. H., Ogdie, A., Gladman, D. D., Deal, C. L., Deodhar, A. A., Dubreuil, M., Dunham, J., Husni, M. E., Kenny, S., et al. (2018) · Journal of Psoriasis and Psoriatic Arthritis · doi:10.1177/2475530318812244 · Cited by 43
Pellegrini, C., Esposito, M., Rossi, E., Gisondi, P., Piaserico, S., Dapavo, P., Conti, A., Gambardella, A., Burlando, M., Narcisi, A., et al. (2022) · Dermatology and Therapy · doi:10.1007/s13555-022-00797-9 · Cited by 34
“New treatment options targeting the interleukin (IL)–23/Th17 axis have shown greater efficacy than traditional psoriasis drugs and even newer anti-tumor necrosis factor (TNF)-a agents [6, 7].”
BackgroundTargeting Th17 Effector Cytokines for the Treatment of Autoimmune Diseases
Yamagata, T., Skepner, J. E., & Yang, J. (2015) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-015-0362-x · Cited by 40
Metadata
- Authors
- Langley, R. G., Elewski, B. E., Lebwohl, M., Reich, K., Griffiths, C. E. M., Papp, K., Puig, L., Nakagawa, H., Spelman, L., Sigurgeirsson, B., Rivas, E., Tsai, T.-F., Wasel, N., Tyring, S., Salko, T., Hampele, I., Notter, M., Karpov, A., Helou, S., & Papavassilis, C.
- Affiliations
- Dalhousie University (CA)
- University of Alabama at Birmingham (US)
- Mount Sinai Hospital (US)
- Dermatologikum Hamburg (DE)
- Manchester Academic Health Science Centre (GB)
- Probity Medical Research (CA)
- Hospital de Sant Pau (ES)
- Jikei University School of Medicine (JP)
- University of Iceland (IS)
- National Taiwan University (TW)
- Center for Clinical Studies (US)
- Novartis (Switzerland) (CH)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-07-24
- Volume
- 371
- Issue
- 4
- Pages
- 326-338
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1973354423
- Cited by
- 1,997
- References
- 25
- Citations by year
- 2026: 96 · 2025: 107 · 2024: 116 · 2023: 142 · 2022: 146 · 2021: 165 · 2020: 198 · 2019: 230 · 2018: 201 · 2017: 223 · 2016: 203 · 2015: 146 · 2014: 19
- FWCI
- 90.34
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research Explorer (The University of Manchester) (acceptedVersion)
- Digital Access to Libraries (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- GRO (submittedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
- Health Sciences › Medicine › Dermatology › Dermatology and Skin Diseases
- Health Sciences › Medicine › Rheumatology › Spondyloarthritis Studies and Treatments
- Keywords
- secukinumab, plaque psoriasis, IL-17A, anti-IL-17A monoclonal antibody, etanercept, PASI 75, dosing regimen, biologic therapy, treatment efficacy and safety, erasure, fixtures, Psoriasis Area and Severity Index
- MeSH terms
- Etanercept, Adult, Antibodies, Antibodies, Monoclonal, Double-Blind Method, Female, Humans, Immunoglobulin A, Immunoglobulin G, Immunosuppressive Agents, Infections, Injections, Subcutaneous, Male, Middle Aged, Psoriasis, Receptors, Tumor Necrosis Factor, Interleukin-17, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.